Benzinga | Apr 16, 2021 07:02AM EDT

Bausch Health Announces VYZULTA 0.024%, Is Now Approved In Brazil

Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company"), Bausch + Lomb, its leading global eye health business, and Nicox (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that VYZULTA(r) (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA -- Ag?ncia Nacional de Vigil?ncia Sanit?ria).